CN113278068A - Monoclonal antibody F5 against novel coronavirus SARS-CoV-2 - Google Patents
Monoclonal antibody F5 against novel coronavirus SARS-CoV-2 Download PDFInfo
- Publication number
- CN113278068A CN113278068A CN202110745540.2A CN202110745540A CN113278068A CN 113278068 A CN113278068 A CN 113278068A CN 202110745540 A CN202110745540 A CN 202110745540A CN 113278068 A CN113278068 A CN 113278068A
- Authority
- CN
- China
- Prior art keywords
- ser
- antibody
- seq
- sequence
- artificial sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 239000012634 fragment Substances 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 59
- 102100031673 Corneodesmosin Human genes 0.000 abstract description 52
- 101710139375 Corneodesmosin Proteins 0.000 abstract description 51
- 238000002823 phage display Methods 0.000 abstract description 44
- 241000711573 Coronaviridae Species 0.000 abstract description 29
- 241000700605 Viruses Species 0.000 abstract description 21
- 230000035772 mutation Effects 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000003472 neutralizing effect Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 63
- 150000001413 amino acids Chemical class 0.000 description 50
- 108020004414 DNA Proteins 0.000 description 32
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 238000005406 washing Methods 0.000 description 18
- 229940098773 bovine serum albumin Drugs 0.000 description 17
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 229920000936 Agarose Polymers 0.000 description 10
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 10
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 10
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 10
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 10
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000004091 panning Methods 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 108010003137 tyrosyltyrosine Proteins 0.000 description 6
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 5
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 5
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 5
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 5
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 5
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 5
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 5
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 5
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 5
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 5
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 5
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 5
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 5
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 5
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 5
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 5
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 5
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 5
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 5
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 5
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 5
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 5
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 5
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 5
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 5
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 5
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 5
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 5
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 5
- 241000880493 Leptailurus serval Species 0.000 description 5
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 5
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 5
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 5
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 5
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 5
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 5
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 5
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 5
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 5
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 5
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 5
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 5
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 5
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 5
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 5
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 5
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 5
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 5
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 5
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 5
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 5
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 5
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 5
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 5
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 5
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 5
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 5
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 5
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 5
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 5
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 5
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 5
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 5
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 5
- 230000001188 anti-phage Effects 0.000 description 5
- 108010008355 arginyl-glutamine Proteins 0.000 description 5
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 5
- 108010078144 glutaminyl-glycine Proteins 0.000 description 5
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 5
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 5
- 108010010147 glycylglutamine Proteins 0.000 description 5
- 108010015792 glycyllysine Proteins 0.000 description 5
- 108010037850 glycylvaline Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 108010044292 tryptophyltyrosine Proteins 0.000 description 5
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 4
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- DCQMJRSOGCYKTR-GHCJXIJMSA-N Ile-Asp-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O DCQMJRSOGCYKTR-GHCJXIJMSA-N 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- WHVTZNGCKIEGPC-UHFFFAOYSA-N 4-(4-aminophenyl)-2,2,6,6-tetramethylcyclohex-3-en-1-amine;hydrochloride Chemical compound Cl.CC1(C)C(N)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 WHVTZNGCKIEGPC-UHFFFAOYSA-N 0.000 description 2
- SDZRIBWEVVRDQI-CIUDSAMLSA-N Ala-Lys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O SDZRIBWEVVRDQI-CIUDSAMLSA-N 0.000 description 2
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 2
- NINQYGGNRIBFSC-CIUDSAMLSA-N Ala-Lys-Ser Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(O)=O NINQYGGNRIBFSC-CIUDSAMLSA-N 0.000 description 2
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 2
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 2
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 2
- 108010062166 Lys-Asn-Asp Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 2
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 2
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 2
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 2
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 2
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 2
- LMMDEZPNUTZJAY-GCJQMDKQSA-N Thr-Asp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O LMMDEZPNUTZJAY-GCJQMDKQSA-N 0.000 description 2
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 2
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 2
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 2
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 1
- NIZKGBJVCMRDKO-KWQFWETISA-N Ala-Gly-Tyr Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NIZKGBJVCMRDKO-KWQFWETISA-N 0.000 description 1
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 description 1
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 1
- HPNDKUOLNRVRAY-BIIVOSGPSA-N Asn-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N)C(=O)O HPNDKUOLNRVRAY-BIIVOSGPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ABLQPNMKLMFDQU-BIIVOSGPSA-N Cys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CS)N)C(=O)O ABLQPNMKLMFDQU-BIIVOSGPSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- KZKBJEUWNMQTLV-XDTLVQLUSA-N Gln-Ala-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZKBJEUWNMQTLV-XDTLVQLUSA-N 0.000 description 1
- RMOCFPBLHAOTDU-ACZMJKKPSA-N Gln-Asn-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RMOCFPBLHAOTDU-ACZMJKKPSA-N 0.000 description 1
- LPYPANUXJGFMGV-FXQIFTODSA-N Gln-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LPYPANUXJGFMGV-FXQIFTODSA-N 0.000 description 1
- CITDWMLWXNUQKD-FXQIFTODSA-N Gln-Gln-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CITDWMLWXNUQKD-FXQIFTODSA-N 0.000 description 1
- RBWKVOSARCFSQQ-FXQIFTODSA-N Gln-Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O RBWKVOSARCFSQQ-FXQIFTODSA-N 0.000 description 1
- OKARHJKJTKFQBM-ACZMJKKPSA-N Gln-Ser-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OKARHJKJTKFQBM-ACZMJKKPSA-N 0.000 description 1
- OACQOWPRWGNKTP-AVGNSLFASA-N Gln-Tyr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O OACQOWPRWGNKTP-AVGNSLFASA-N 0.000 description 1
- UBRQJXFDVZNYJP-AVGNSLFASA-N Gln-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O UBRQJXFDVZNYJP-AVGNSLFASA-N 0.000 description 1
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- SCJJPCQUJYPHRZ-BQBZGAKWSA-N Gly-Pro-Asn Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O SCJJPCQUJYPHRZ-BQBZGAKWSA-N 0.000 description 1
- WDXLKVQATNEAJQ-BQBZGAKWSA-N Gly-Pro-Asp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WDXLKVQATNEAJQ-BQBZGAKWSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- QYOGJYIRKACXEP-SLBDDTMCSA-N Ile-Asn-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N QYOGJYIRKACXEP-SLBDDTMCSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- YCKPUHHMCFSUMD-IUKAMOBKSA-N Ile-Thr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCKPUHHMCFSUMD-IUKAMOBKSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 1
- FVFUOQIYDPAIJR-XIRDDKMYSA-N Ser-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N FVFUOQIYDPAIJR-XIRDDKMYSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- MFEBUIFJVPNZLO-OLHMAJIHSA-N Thr-Asp-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O MFEBUIFJVPNZLO-OLHMAJIHSA-N 0.000 description 1
- JQAWYCUUFIMTHE-WLTAIBSBSA-N Thr-Gly-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JQAWYCUUFIMTHE-WLTAIBSBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- BEIGSKUPTIFYRZ-SRVKXCTJSA-N Tyr-Asp-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O BEIGSKUPTIFYRZ-SRVKXCTJSA-N 0.000 description 1
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 229940120922 lopinavir and ritonavir Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a phage display antibody library and screens five antibodies which can be combined with S protein of new coronavirus SARS-CoV-2. the invention is based on synthetic biology and phage display technology, the mutation is introduced into the super-variable region of antibody variable region, and the gene is transferred into colibacillus, thereby constructing antibody library containing 108A synthetic antibody library of seed antibodies; the phage display antibody library can screen and obtain antibodies with specificity and detection functions, and expands powerful resources for biological research and medical diagnosis; five S proteins capable of following the new coronavirus are screenedThe combined antibody can be used for detecting viruses, part of the antibody can block the combination of the viruses and cells, has the capability of neutralizing the infectivity of the new coronavirus, can be used for preparing a new coronavirus detection product, preparing a new coronavirus inhibition drug and preparing a drug preparation for preventing or treating diseases caused by the new coronavirus, and has wide application prospect.
Description
This application is application No. 202010499744.8, title of invention: the application date of the mother case is 2020, 06 and 04 days.
Technical Field
The invention relates to the technical field of biomedicine and molecular biology, in particular to a phage display antibody library and a monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained by panning based on the phage display antibody library.
Background
Compared with the original coronavirus, SARS-CoV-2 is not only transmissible in severe patients, but also has mild symptoms and strong infectivity in latent patients, and has a plurality of propagation ways, and can be propagated through droplets and contact, thereby bringing great difficulty to prevention.
Various treatment schemes are provided for treating the new coronary pneumonia in various countries, mainly including small molecular drugs of rituxivir, chloroquine and hydroxychloroquine, lopinavir and ritonavir and three drugs of lopinavir, ritonavir and interferon are used in combination, unfortunately, no obvious treatment effect exists, and some drugs have serious toxic and side effects. On the other hand, antibody drugs play an important role in the treatment of infectious diseases, autoimmune diseases, tumors, and the like. Under the conditions of high mutation rate of SARS-CoV-2, difficult development of new coronary pneumonia vaccine, long period, great side effect of traditional medicine and no effect, the serum of recovered patient is used in treating severe patient to result in relatively effective treating scheme and certain effect in practical treatment, and this shows that the antibody of new coronary virus can weaken the infection capacity of SARS-CoV-2 virus effectively and has certain effect in treating new coronary pneumonia patient.
The SARS-CoV-2 virus has a diameter of 75-160 nm, its genome is continuous linear single-stranded RNA, and its genome can be used for successively coding nucleoprotein (nucleoprotein), envelope protein (envelope protein), membrane protein (membrane protein) and spinous process protein (spike protein, also called S-protein or S protein), in which the spinous process protein is the most important protein on its surface, and its main function is to determine host range and specificity of virus, and can be combined and fused with host cell membrane receptor to implement infection of cell. The spinous process protein has two subunits S1 and S2, the Receptor Binding Domain (RBD) in S1, and interacts with the human SARS-CoV receptor angiotensin converting enzyme II (ACE2) molecule, and S2 contains the essential elements required for the membrane fusion process, and realizes the fusion of virus and cell. Therefore, the human monoclonal antibody of the S protein can theoretically block the combination of virus and cells, has the capability of weakening virus infection, and can be used as an antibody medicament for treating patients with new coronavirus pneumonia.
Antibodies are important glycoprotein molecules in the mammalian immune system. The antibody molecule consists of two Heavy chains (Heavy chain) and two Light chains (Light chain), wherein the Heavy chains are divided into Variable regions (VH) and three Constant regions (Constant regions of Heavy chain; CH1, CH2, CH3), and the Light chains consist of one Variable region (VL) and one Constant region (CL). The variable region has a function of binding to an antigen, and varies depending on the individual antibody, while the constant region of the antibody varies depending on the species and subtype of the antibody. The variable region of the antibody is further divided into 4 Framework regions (Framework; FR1, FR2, FR3 and FR4) and three Complementarity determining regions (complementary-determining regions; CDR1, CDR2 and CDR3), wherein the heavy chain variable region of the antibody has the structure HFR1-CDRH1-HFR2-CDRH2-HFR3-CDRH3-HFR4, and the light chain variable region of the antibody has the structure LFR1-CDRL1-LFR2-CDRL2-LFR3-CDRL3-LFR4, wherein the Complementarity determining regions are also called hypervariable regions and are directly combined with the epitope of the antigen.
Disclosure of Invention
In order to solve the problems, the invention aims to provide a phage display antibody library and a monoclonal antibody aiming at the novel coronavirus SARS-CoV-2 obtained by panning based on the phage display antibody library.
In order to achieve the purpose, the invention is realized by the following technical scheme:
a phage display antibody library comprises a DNA sequence of an antibody heavy chain variable region, which is obtained by mutating amino acids corresponding to all mutation positions of the antibody heavy chain variable region into any amino acid by using NNK codons; mutating amino acids corresponding to all mutation positions of the antibody light chain variable region into any amino acid, and correspondingly obtaining a DNA sequence of the antibody light chain variable region; the heavy chain variable region gene and the light chain variable region gene of the antibody are recombined with a phage vector to construct plasmids and then transformed into escherichia coli, thereby constructing a phage display antibody library;
wherein the mutation positions of the antibody heavy chain variable region are 50, 52a, 52b, 53, 55, 56, 58, 97, 98, 99, 100, 101, 102, 103, 104, 105; the mutation positions of the variable region of the antibody light chain are 50, 51, 52, 53, 89, 90, 91, 92, 93, 94, 95, 96 and 97;
wherein the DNA sequence of the heavy chain variable region of the antibody library is SEQ ID NO: 53;
the DNA sequence of the variable region of the light chain of the antibody library is SEQ ID NO: 54.
the invention also comprises a construction method of the phage display antibody library, which comprises the following steps:
amplifying an HFR1-CDHR1-HFR2 gene fragment VH1 of an antibody heavy chain variable region VH by a polymerase chain reaction by using a primer SfiVHback and a primer VHFR2For as a template, amplifying a gene of CDRH2-HFR3-CDRH3-HFR4, namely VH2 by using a degenerate primer CDRH2 libpack and a degenerate primer CDRH3lib9For, and performing agarose electrophoresis to confirm the amplified VH1 and VH 2; cutting out and purifying the two gene segments, and performing overlapping PCR by using two gene sequences as templates and primers SfiVHback and XhoVHfor; performing agarose electrophoresis, confirming the amplified DNA fragment, purifying the DNA fragment, and using the DNA fragment as a heavy chain variable region gene of a phage display antibody library;
wherein the DNA sequence of the antibody heavy chain variable region template is SEQ ID NO: 1;
the base sequence of the primer SfiVHback is SEQ ID NO: 2;
the base sequence of the primer VHFR2For is SEQ ID NO: 3;
the base sequence of the degenerate primer CDRH2 libpack is SEQ ID NO: 4;
the base sequence of the degenerate primer CDRH3lib9for is SEQ ID NO: 5;
the base sequence of xhohfor is SEQ ID NO: 6;
the DNA sequence of the heavy chain variable region of the antibody library is SEQ ID NO: 53;
amplifying LFR1-CDRL1-LFR2 gene fragment VL1 of the antibody light chain VL by polymerase chain reaction with a primer SalVLback and a primer VLFR2For by using an antibody light chain variable region DNA as a template, amplifying the gene fragment VL2 of CDRL2-LFR3-CDRL3-LFR4 with a degenerate primer CDRL2libback and a degenerate primer CDRL3libfor, performing agarose electrophoresis, confirming the amplified VL1 and VL2, purifying the two gene fragments, cutting out the two gene sequences as templates, and performing overlap PCR with the primers SalVLback and NotVLfor; performing agarose electrophoresis, confirming the amplified DNA fragment, purifying the DNA fragment, and using the DNA fragment as a light chain variable region gene of a phage display antibody library;
wherein the DNA sequence of the antibody light chain variable region template is SEQ ID NO: 7;
the base sequence of the primer SalVLback is SEQ ID NO: 8;
the base sequence of the primer VLFR2For is SEQ ID NO: 9;
the base sequence of the degenerate primer CDRL2 libpack is SEQ ID NO: 10;
the base sequence of the degenerate primer CDRL3libfor is SEQ ID NO: 11;
the base sequence of NotVLfor is SEQ ID NO: 12;
the DNA sequence of the variable region of the light chain of the antibody library is SEQ ID NO: 54, a first electrode;
processing the light chain variable region gene by using restriction enzymes SalI and NotI, cloning the light chain variable region gene into a phage display vector pDOng1 after purification, processing the light chain variable region gene by using restriction enzymes SfiI and XhoI after amplification, connecting the light chain variable region gene with the heavy chain variable region gene processed by the restriction enzymes SfiI and XhoI by using T4 DNA ligase, and transforming escherichia coli TG-1;
and fourthly, culturing and transforming the Escherichia coli TG-1, adding the auxiliary phage KM13 for infection, and carrying out post-treatment to obtain a phage display antibody library.
The invention also includes monoclonal antibody A9 panned from phage display antibody library,
the amino acid sequence of the heavy chain variable region of the A9 antibody is SEQ ID NO: 13, CDRH1 amino acid sequence is SEQ ID NO: 14; the amino acid sequence of CDRH2 is SEQ ID NO: 15; the amino acid sequence of CDRH3 is SEQ ID NO: 16;
the amino acid sequence of the variable region of the light chain of the A9 antibody is SEQ ID NO: 17, the amino acid sequence of CDRL1 is SEQ ID NO: 18; the amino acid sequence of CDRL2 is SEQ ID NO: 19; the amino acid sequence of CDRL3 is SEQ ID NO: 20.
the invention also includes monoclonal antibody E11 panned from the phage display antibody library,
the amino acid sequence of the heavy chain variable region of the E11 antibody is SEQ ID NO: 21, CDRH1 amino acid sequence is SEQ ID NO: 22; the amino acid sequence of CDRH2 is SEQ ID NO: 23; the amino acid sequence of CDRH3 is SEQ ID NO: 24;
the amino acid sequence of the variable region of the E11 antibody light chain is SEQ ID NO: 25, CDRL1 amino acid sequence is SEQ ID NO: 26; the amino acid sequence of CDRL2 is SEQ ID NO: 27; the amino acid sequence of CDRL3 is SEQ ID NO: 28.
the invention also includes monoclonal antibody F5 panned from the phage display antibody library,
the amino acid sequence of the heavy chain variable region of the F5 antibody is SEQ ID NO: 29, CDRH1 amino acid sequence is SEQ ID NO: 30, of a nitrogen-containing gas; the amino acid sequence of CDRH2 is SEQ ID NO: 31; the amino acid sequence of CDRH3 is SEQ ID NO: 32, a first step of removing the first layer;
the amino acid sequence of the variable region of the F5 antibody light chain is SEQ ID NO: 33, CDRL1 amino acid sequence of SEQ ID NO: 34; the amino acid sequence of CDRL2 is SEQ ID NO: 35; the amino acid sequence of CDRL3 is SEQ ID NO: 36.
the invention also includes monoclonal antibody F10 panned from the phage display antibody library,
the amino acid sequence of the heavy chain variable region of the F10 antibody is SEQ ID NO: 37, CDRH1 amino acid sequence is SEQ ID NO: 38; the amino acid sequence of CDRH2 is SEQ ID NO: 39; the amino acid sequence of CDRH3 is SEQ ID NO: 40;
the amino acid sequence of the variable region of the F10 antibody light chain is SEQ ID NO: 41 and the amino acid sequence of CDRL1 is SEQ ID NO: 42; the amino acid sequence of CDRL2 is SEQ ID NO: 43; the amino acid sequence of CDRL3 is SEQ ID NO: 44.
the invention also includes monoclonal antibody H9 panned from phage display antibody library,
the amino acid sequence of the heavy chain variable region of the H9 antibody is SEQ ID NO: 45, the amino acid sequence of CDRH1 is SEQ ID NO: 46; the amino acid sequence of CDRH2 is SEQ ID NO: 47; the amino acid sequence of CDRH3 is SEQ ID NO: 48;
the amino acid sequence of the variable region of the H9 antibody light chain is SEQ ID NO: 49, CDRL1 amino acid sequence of SEQ ID NO: 50; the amino acid sequence of CDRL2 is SEQ ID NO: 51; the amino acid sequence of CDRL3 is SEQ ID NO: 52.
the invention also comprises the application of any monoclonal antibody (A9, E11, F5, F10 and H9) panned by the phage display antibody library in preparing a novel coronavirus SARS-CoV-2 detection product; for example, the kit can be prepared to detect the new coronavirus SARS-CoV-2, and the kit contains any one or more of A9, E11, F5, F10 and H9 antibodies and derivatives thereof, such as full-length antibodies containing antibody variable regions, scFv, or Fab fragments or other forms of fusion proteins containing variable regions and auxiliary materials of other assembly kits.
The invention also comprises the application of any monoclonal antibody (A9, E11, F5, F10 and H9) panned by the phage display antibody library in the preparation of medicaments for inhibiting the novel coronavirus SARS-CoV-2.
The invention also comprises the application of any monoclonal antibody (A9, E11, F5, F10 and H9) panned by the phage display antibody library in preparing a pharmaceutical preparation for preventing or treating diseases caused by the novel coronavirus SARS-CoV-2.
The invention also includes any engineered monoclonal antibody, the antigen binding fragment of which is an antibody fragment selected from any of monoclonal antibodies a9, E11, F5, F10, H9, including Fab, Fab '-SH, Fv, scFv, or (Fab') 2 fragments.
Antibodies are divided into variable and constant regions, with the variable region determining the antigen binding properties of the antibody. The antibody variable region sequences involved in the present invention can be used to make Fab, Fab '-SH, Fv, scFv or (Fab') 2 fragments with the same antigen binding specificity and application.
The invention also includes any monoclonal antibody, the heavy chain and light chain of the hypervariable region of the amino acid sequence and any monoclonal antibody A9, E11, F5, F10 or H9 corresponding sequences have more than 80% of the same.
The hypervariable region sequence of the antibody is further mutated and evolved, and under the condition of keeping 80% of the same property, the antigen binding specificity of the antibody is unchanged, and the antigen binding capacity can be obviously improved.
Compared with the prior art, the invention has the following advantages:
the invention is based on synthetic biology and phage display technology, introduces mutation into specific position of antibody including hyper-variable region, and transfers the gene into Escherichia coli, thereby constructing a gene containing 108A diverse synthetic antibody library capable of high-efficiency expression in Escherichia coli; the phage display antibody library can be used for screening and obtaining antibodies with specificity and detection functions, and powerful resources of biological research and medical diagnosis are expanded.
The invention also screens five antibodies which can be combined with the S protein of the new coronavirus SARS-CoV-2 from the phage display antibody library, the hyper-variable sequence of the antibody is a new sequence, and the antibody is a new humanized monoclonal antibody; the antibody can block the combination of virus and cell, has the ability of neutralizing the infectivity of new coronavirus, can be used in preparing SARS-CoV-2 detecting product, SARS-CoV-2 inhibiting medicine and SARS-CoV-2 preventing and treating medicine preparation, and has wide application foreground.
Drawings
FIG. 1 is an agarose electrophoresis of the gene fragment obtained by PCR;
FIG. 2 is the result of enzyme-linked immunoassay for the antigen binding ability of phage obtained by panning antibody library;
FIG. 3 shows the results of ELISA test for monoclonal antibody antigen specificity;
FIG. 4 is a schematic diagram of the principle of detecting new coronavirus using elutriated antibody;
FIG. 5 shows the results of ELISA using Fab fragment of A9 antibody in combination with F5, F10 or H9 to detect virus S protein;
FIG. 6 shows the results of ELISA assays for detecting viral S protein using Fab fragment of E11 antibody in combination with F5, F10 or H9.
Detailed Description
The invention aims to provide a phage display antibody library and a monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained by panning based on the phage display antibody library, which is realized by the following technical scheme:
the invention is further described with reference to specific examples.
The S protein and the virus S-RBD protein of the novel coronavirus SARS-CoV-2 used in the examples were purchased from Beijing Yiqian Shenzhou Biotech Co.
References to the synthesis of the phage display vector pDong1 are: dong, et al, Anal biochem.2009,386(1): 36-44.
Example 1
Construction of phage display antibody library
Using synthetic antibody heavy chain variable region DNA (base sequence SEQ ID NO: 1) as a template, amplifying HFR1-CDRH1-HFR2 gene fragment VH1 of antibody heavy chain variable region VH by polymerase chain reaction using primers SfiVHback (base sequence SEQ ID NO: 2) and VHFR2For (base sequence SEQ ID NO: 3), amplifying gene VH2 of CDRH2-HFR3-CDRH3-HFR4 using degenerate primer CDRH2 liback (base sequence SEQ ID NO: 4) and degenerate primer CDRH3lib9For (base sequence SEQ ID NO: 5), performing agarose electrophoresis, confirming the amplified VH1 and VH2, cutting out and purifying the two gene fragments, performing overlapping PCR using two gene sequence templates, using primers SfiVHback (base sequence SEQ ID NO: 2) and XhoVHfor (base sequence SEQ ID NO: 6);
KOD-plus-neo (toyobo bio) was used for the above PCR reactions, the reaction system was 50 μ L, the DNA template was 50ng, the primer concentration was 1 μ M, the reaction conditions were 94 degrees of denaturation for 2 minutes, 55 degrees of quenching for 30 seconds, the DNA extension reaction was run at 68 degrees for 1 minute, 30 cycles were performed in total, agarose electrophoresis was performed, the amplified DNA fragment was confirmed, and the DNA fragment was excised and purified as a heavy chain variable region gene of the phage display antibody library, the base sequence of which was SEQ ID NO: 53.
using synthetic antibody light chain DNA (base sequence SEQ ID NO: 7) as a template, LFR1-CDRL1-LFR2 gene fragment VL1 of antibody light chain VL was amplified by polymerase chain reaction using primers SalVLback (base sequence SEQ ID NO: 8) and VLFR2For (base sequence SEQ ID NO: 9), and CDRL2 liback (base sequence SEQ ID NO: 10) and degenerate primer CDRL3libfor (base sequence SEQ ID NO: 11) to amplify gene fragment VL2 of CDRL2-LFR3-CDRL3-LFR4, agarose electrophoresis was performed to confirm amplified VL1 and VL2, the two gene fragments were excised and purified, and then two gene sequences were used as templates, and overlap PCR was performed using primers SalVLback (base sequence SEQ ID NO: 8) and NotVLfor (base sequence SEQ ID NO: 12).
KOD-plus-neo (TOYOBO Bio) was used for the above PCR reactions, the reaction system was 50. mu.L, the DNA template was 50ng, the primer concentration was 1. mu.M, the reaction conditions were 94 degrees of denaturation for 2 minutes, 55 degrees of quenching for 30 seconds, and the DNA extension reaction was carried out at 68 degrees for 1 minute for 30 cycles. Performing agarose electrophoresis, and purifying the PCR amplified DNA fragment as a light chain gene of a phage display antibody library, wherein the base sequence of the DNA fragment is SEQ ID NO: 54.
the light chain variable region gene was treated with 10 units of restriction enzymes SalI and NotI at 37 degrees for 3 hours, purified and then cloned into phage display vector pDeng 1. The successfully cloned plasmid (containing the light chain variable region gene) was amplified and further treated with 10 units of SfiI and XhoI, and ligated with the antibody heavy chain variable region gene treated with the same enzymes (SfiI and XhoI) at 16 ℃ using T4 DNA ligase to transform E.coli TG-1;
culturing and transforming 25mL of Escherichia coli to OD at 37 DEG C600To 0.5, the helper phage KM13 was added, and after infection at 37 ℃ for 1 hour, 3000g was centrifuged for 30 minutes, the supernatant was discarded, and 50mL (1.6% Tryptone, 1% Yeast Ex) of 2YT medium containing 100. mu.g/mL ampicillin, 50. mu.g/mL kanamycin and 0.1% glucose was usedtrack, 0.5% NaCl), 30 ℃, 250rpm, shaking the bacteria for 16 hours, centrifuging the culture solution for 30 minutes at 5000g the next day, separating and recovering 40mL of supernatant, adding 10mL of PEG/NaCl solution into the supernatant, mixing uniformly, placing on ice for 30 minutes, 5000g, centrifuging for 30 minutes, discarding the supernatant, adding 2mL of sterilized PBS solution to dissolve the precipitate, and using the precipitate as a phage display antibody library solution.
The agarose electrophoresis picture of the amplified synthetic antibody library variable region gene is shown in figure 1, wherein VL1 and VL2 are two fragments of the synthetic antibody library light chain variable region gene, and VL is the gene of the antibody library light chain variable region; VH1 and VH2 are two fragments of the heavy chain variable region gene of the synthetic antibody library, and VH is the heavy chain variable region gene of the antibody library; lane M is DNA marker; successfully amplifying antibody variable region gene, wherein the length of heavy chain variable region gene is about 400bp, the length of light chain variable region gene is about 370bp, cloning the above gene fragments to phage display carrier pDeng 1, making phage by using Escherichia coli TG-1, and finally obtaining a gene containing about 10 bp8Phage display antibody libraries of seed antibodies.
The obtained phage display antibody library comprises a DNA sequence which is obtained by mutating amino acids corresponding to the mutation positions of the heavy chain variable regions of the antibodies into any amino acid by utilizing NNK codons and correspondingly obtaining the heavy chain variable regions of the antibodies; and mutating the amino acid corresponding to the mutation position of the antibody light chain variable region into any amino acid, and correspondingly obtaining the DNA sequence of the antibody light chain variable region; the heavy chain variable region gene and the light chain variable region gene of the antibody are recombined with a phage vector to construct plasmids and then transformed into escherichia coli, thereby constructing a phage display antibody library;
wherein the mutation positions of the antibody heavy chain variable region are 50, 52a, 52b, 53, 55, 56, 58, 97, 98, 99, 100, 101, 102, 103, 104, 105; the mutation positions of the variable region of the antibody light chain are 50, 51, 52, 53, 89, 90, 91, 92, 93, 94, 95, 96 and 97;
wherein the DNA sequence of the heavy chain variable region of the antibody is SEQ ID NO: 53;
the DNA sequence of the antibody light chain variable region is SEQ ID NO: 54.
second, panning of phage display antibody library
mu.L of PBS containing SARS-CoV-2 virus S protein 10. mu.g/ml was added to each of 10 wells of a 96-well microplate, incubated overnight at 4 ℃ and the antigen solution was discarded the next time, 200. mu.L of PBS containing 2% skim milk powder was added to each well, incubated at 25 ℃ for 2 hours for blocking, washed 3 times with PBST, and 100. mu.L of phage solution (R0; 10 in each well) was added to each well9cfu phage) incubated at room temperature for 2 hours, after washing with PBST, 100 μ L trypsin per well was added to elute phage bound to viral S protein;
culturing TG-1 Escherichia coli to OD600 of 0.4, taking 4mL bacterial liquid, adding 500 μ L dissolved phage solution into the bacterial liquid, infecting at 37 ℃ for 30 minutes, centrifuging at 5000g for 20 minutes, discarding the supernatant, suspending the bacterial cells with 2YT culture medium containing 100 μ g/mL ampicillin, 50 μ g/mL kanamycin and 0.1% glucose, shaking the bacterial cells at 30 ℃, 250rpm for 16 hours, centrifuging at 5000g the next day for 30 minutes, separating and recovering the supernatant, adding 1/5-volume PEG/NaCl solution into the supernatant solution, mixing uniformly, placing on ice for 30 minutes, centrifuging at 5000g for 30 minutes, discarding the supernatant, adding 200 μ L sterilized PBS solution as phage solution after the first enrichment (R1); repeating the steps to respectively obtain phage solutions R2 and R3; and performing enzyme-linked immunosorbent assay, and verifying the binding specificity and binding performance of the phage display antibody library obtained in the panning process and the new coronavirus SARS-CoV-2.
The enzyme-linked immunosorbent assay was performed as follows: adding 100 μ L PBS solution containing neocoronavirus S protein solution (2 μ g/mL) or bovine serum albumin BSA (2 μ g/mL) into 96-well plate, overnight at 4 deg.C, discarding antigen solution the next day, adding 200 μ L solution containing 2% skimmed milk powder, incubating at 25 deg.C for 2 hr, blocking the plate, washing the plate with PBS solution containing 0.1% Tween 20 for 3 times, and adding diluted solutions of R0, R1, R2 and R3 phage (10 μ g/mL)9cfu/well) at 25 ℃ for 1 hour, washing the microplate with PBST solution, adding HRP-labeled mouse anti-M13 phage antibody, after 1 hour incubation, washing the plate with PBST, adding HRP substrate TMBZ (prepared with sodium acetate solution pH6.0, containing 1/10000 diluted 30% H2O2) After color developmentAnd (3) measuring the absorbance at 450nm by using a microplate reader, drawing a histogram, and comparing the binding performance of the phage antibody obtained in each step with the S protein and the BSA.
The results of the enzyme-linked immunosorbent assay are shown in fig. 2, and when the binding capacities of the phage libraries R0, R1, R2 and R3 obtained in the phage panning process and the S protein are compared, it is found that the binding capacity of the phage solution R3 and the S protein obtained in the third panning is significantly increased, while the binding performance to BSA is very weak and unchanged, which indicates that the antibodies against the new coronavirus S protein in the constructed phage display antibody library are enriched.
Thirdly, screening of monoclonal antibody
Culturing TG-1 Escherichia coli to OD600 of 0.4, taking 100 mu L of elutriation sieve R3 phage antibody library dissolved out phage solution, using the phage solution to infect 200 mu L of Escherichia coli bacterial liquid, incubating for 30 minutes at 37 ℃, coating the bacterial liquid on a 2YT culture medium plate containing 100 mu g/mL ampicillin, 50 mu g/mL kanamycin and 1% glucose, culturing overnight at 37 ℃, selecting 96 colonies on the next day, inoculating the colonies on a culture plate with 96 wells, culturing at 37 ℃ to OD600 of 0.4, adding M13 phage into each well, centrifuging for 20 minutes at 5000g after infection, removing supernatant, adding 200 mu L of 2YT culture medium containing 100 mu g/mL ampicillin, 50 mu g/mL kanamycin and 0.1% glucose into each well, suspending thalli, and culturing for 16 hours at the speed of 30 ℃ and 250 rpm; centrifuging the culture solution for 30 minutes at 5000g the next day, separating and recovering the supernatant, performing enzyme-linked immunosorbent assay, and verifying the binding specificity and binding performance of each monoclonal antibody and the new coronavirus S protein.
The enzyme-linked immunosorbent assay was performed as follows: 100 μ L of PBS solution containing virus S protein (1 μ g/mL) was added to a 96-well plate, overnight at 4 ℃, the antigen solution was discarded the next day, 200 μ L of a solution containing 2% skim milk powder was added, incubation was performed at 25 ℃ for 2 hours, and the plate was blocked. Washing the ELISA plate with PBS solution containing 0.1% Tween 20 for 3 times, adding phage solution, incubating at 25 deg.C for 1 hr, washing the ELISA plate with PBST solution, adding HRP-labeled mouse anti-M13 antibody, incubating for 1 hr, washing the plate with PBST, adding HRP substrate TMBZ (prepared with sodium acetate solution of pH6.0, containing 1/10000 diluted 30% H)2O2) Color developmentThen, absorbance at 450nm was measured with a microplate reader, and the binding properties of the phage antibody prepared by each clone to S protein and bovine serum albumin were compared.
According to the test results, 5 strains of antibodies A9, E11, F5, F10 and H9 are combined with S protein, plasmids are extracted for gene sequencing, 5 strains of antibody genes with different sequences are obtained, and the same sequences as the antibody genes in the invention are not found by comparing the extracted sequences with the registered antibody sequences in an antibody gene library, so that the sequences are novel antibodies, and the amino acid sequences of the antibodies are as follows:
the heavy chain variable region sequence of the A9 antibody is SEQ ID NO: 13, CDRH1 sequence of SEQ ID NO: 14; the CDRH2 sequence is SEQ ID NO: 15; the CDRH3 sequence is SEQ ID NO: 16;
the variable region sequence of the light chain of the A9 antibody is SEQ ID NO: 17, CDRL1 sequence of SEQ ID NO: 18; the CDRL2 sequence is SEQ ID NO: 19; the CDRL3 sequence is SEQ ID NO: 20;
the variable region sequence of the E11 antibody heavy chain is SEQ ID NO: 21, CDRH1 sequence of SEQ ID NO: 22; the CDRH2 sequence is SEQ ID NO: 23; the CDRH3 sequence is SEQ ID NO: 24;
the variable region sequence of the E11 antibody light chain is SEQ ID NO: 25, CDRL1 sequence of SEQ ID NO: 26; the CDRL2 sequence is SEQ ID NO: 27; the CDRL3 sequence is SEQ ID NO: 28;
the variable region sequence of the F5 antibody heavy chain is SEQ ID NO: 29, CDRH1 sequence of SEQ ID NO: 30, of a nitrogen-containing gas; the CDRH2 sequence is SEQ ID NO: 31; the CDRH3 sequence is SEQ ID NO: 32, a first step of removing the first layer;
the variable region sequence of the F5 antibody light chain is SEQ ID NO: 33, CDRL1 sequence SEQ ID NO: 34; the CDRL2 sequence is SEQ ID NO: 35; the CDRL3 sequence is SEQ ID NO: 36;
the variable region sequence of the F10 antibody heavy chain is SEQ ID NO: 37, CDRH1 sequence of SEQ ID NO: 38; the CDRH2 sequence is SEQ ID NO: 39; the CDRH3 sequence is SEQ ID NO: 40;
the variable region sequence of the F10 antibody light chain is SEQ ID NO: 41, CDRL1 sequence is SEQ ID NO: 42; the CDRL2 sequence is SEQ ID NO: 43; the CDRL3 sequence is SEQ ID NO: 44;
the heavy chain variable region sequence of the H9 antibody is SEQ ID NO: 45, CDRH1 sequence is SEQ ID NO: 46; the CDRH2 sequence is SEQ ID NO: 47; the CDRH3 sequence is SEQ ID NO: 48;
the variable region sequence of the H9 antibody light chain is SEQ ID NO: 49, CDRL1 sequence of SEQ ID NO: 50; the CDRL2 sequence is SEQ ID NO: 51; the CDRL3 sequence is SEQ ID NO: 52;
fourth, antigen specificity of monoclonal antibody
Adding 100 mu L of new coronavirus S protein, S-RBD protein and BSA with the concentration of 1 mu g/mL into a 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the protein solution the next time, adding 200 mu L of 2% skimmed milk powder solution, incubating for 2 hours at 25 ℃, and sealing the enzyme label plate; after washing the microplate 3 times with PBS containing 0.1% Tween 20, 100. mu.L of diluted phage display antibody solution was added to each well, incubated at 25 ℃ for 1 hour, the microplate was washed with PBST solution, HRP-labeled mouse anti-M13 antibody was added, and after incubation for 1 hour, the microplate was washed with PBST, and HRP substrate TMBZ (prepared with sodium acetate solution pH6.0, containing 1/10000 diluted 30% H) was added2O2) After the development, absorbance at 450nm was measured with a microplate reader, a histogram was plotted, and the binding properties of the phage antibody produced by each clone and the envelope protein were compared.
The results of ELISA are shown in FIG. 3, in which antibodies A9 and E11 bind to S protein and S-RBD protein, and antibodies F5, F10 and H9 bind to S protein but have weak binding ability to RBD, indicating that they mainly bind to other regions of S protein, as antibodies recognizing RBD region of S protein. In addition, the antibodies do not bind to the coated BSA, indicating that the antibodies do not bind to BSA, and thus, it can be concluded that the binding of the antibodies A9, E11, F5, F10, H9 to the S protein and the S-RBD protein is specific.
Fifthly, detecting the new coronavirus S protein by using the Fab fragment of the A9 antibody and F5, F10 or H9 antibody displayed by phage
The detection principle is shown in FIG. 4, and the detection method utilizes A9 protein and F5, F10 and H9 displayed by phage, detecting the S protein of the new coronavirus, coating Fab fragment of A9 antibody in the hole of a 96-hole micropore plate, sealing the micropore plate, adding S protein or BSA protein, washing the plate, adding phage display F5 antibody, adding anti-phage antibody labeled with horse radish peroxidase, washing the plate, adding substrate for color development, when the sample does not contain new coronavirus S protein or BSA protein, the reaction system does not develop color, when virus S protein exists, the system develops color, and the more virus S protein in the sample, the more F5 phage are captured to the enzyme label plate by the virus S1 protein, the more anti-phage antibodies are captured correspondingly, the darker the color of the enzyme substrate is developed, and the method can be used for judging whether the virus S1 protein exists in the sample, the method can also be used to detect the presence of SARS-CoV-2 virus in a sample.
The specific operation is as follows: adding A9 antibody Fab fragment into the hole of 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the liquid in the hole, adding 200 μ L of 2% skimmed milk powder solution, standing at room temperature for two hours, and sealing the enzyme label plate. After washing the plate, 100. mu.L of a solution containing the S protein of the novel coronavirus or a Bovine Serum Albumin (BSA) solution was added to the wells, incubated at 25 ℃ for 1 hour, the well-containing solution was removed, the plate was washed with a PBS solution (PBST solution) containing 0.1% Tween, and a phage-displayed F5 antibody solution (10) was added9cfu/mL), incubation for 1 hour at 25 ℃, adding an anti-phage antibody solution (1 mu g/mL) marked with horseradish peroxidase (HRP) after plate washing, incubation for 1 hour at 25 ℃, removing the solution in the wells, washing the plates for 3 times by PBST, finally adding an HRP substrate 3,3,5, 5-tetramethylbenzidine hydrochloride (TMBZ) solution for color development, measuring the absorbance of the solution in the wells at 450nm, making a histogram, and comparing the binding capacity of the antibody with the new coronavirus S protein and bovine serum albumin.
The phage display of F5 antibody solution was changed to F10 or H9 and the same procedure was followed to prepare a histogram, comparing the binding ability of the antibody to the S protein of neocoronavirus and bovine serum albumin.
As shown in FIG. 5, the A9 antibody was combined with phage-displayed F5, F10, or H9, respectively, to detect the virus S protein, with the horizontal axis representing the name of the antibody combined with A9 and the vertical axis representing the absorbance of the solution in the corresponding well. The absorbance of the wells containing the virus S protein enzyme label in the solution formed by combining A9 and F5 is 0.45, while the absorbance of the wells added with BSA is 0.03, which indicates that the combination of A9 and F5 can be used for detecting the new coronavirus S protein in the solution, and the combination of the A9 antibody and F10 and H9 obtains similar results, and indicates that the combination of the A9 antibody and F5, F10 or H9 antibody can detect whether the new coronavirus S protein and the new coronavirus S exist in the sample.
Sixthly, detecting the novel coronavirus S protein by using the Fab fragment of the E11 antibody and F5, F10 or H9 antibody displayed by phage
The detection principle is shown in FIG. 4, and the Fab fragment of the E11 antibody and F5, F10 and H9 displayed by phage are used for detecting the S protein of the novel coronavirus. And (2) coating Fab fragments of the E11 antibody in the holes of a 96-hole microplate, sealing the microplate, adding the S protein, washing the plate, adding a phage display F5 antibody, adding an anti-phage antibody labeled with horseradish peroxidase, washing the plate, and adding a substrate for color development. When the sample has no new coronavirus S protein or BSA, the reaction system does not develop color; when the virus S protein exists, the system develops color, and the more the virus S protein exists in the sample, the more F5 bacteriophage captured to the enzyme label plate through the virus S1 protein, the more corresponding captured anti-bacteriophage antibody, and the darker the color after the substrate added with the enzyme develops color. The method can be used for judging whether the sample has the S1 protein of the virus or not, and can also be used for detecting whether the sample contains the SARS-CoV-2 virus or not.
The specific operation is as follows:
adding the E11 antibody fragment into the hole of the 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the liquid in the hole, adding 200 mu L of 2% skimmed milk powder solution, standing for two hours at room temperature, and sealing the enzyme label plate. After washing the plate, 100. mu.L of a solution containing the S protein of the novel coronavirus or a Bovine Serum Albumin (BSA) solution was added to the wells, incubated at 25 ℃ for 1 hour, the well-containing solution was removed, the plate was washed with a PBS solution (PBST solution) containing 0.1% Tween, and a phage-displayed F5 antibody solution (10) was added9cfu/mL), incubation for 1 hour at 25 ℃, adding an anti-phage antibody solution (1 mu g/mL) marked with horseradish peroxidase (HRP) after plate washing, incubation for 1 hour at 25 ℃, removing the solution in the wells, washing the plates for 3 times by PBST, finally adding an HRP substrate 3,3,5, 5-tetramethylbenzidine hydrochloride (TMBZ) solution for color development, measuring the absorbance of the solution in the wells at 450nm, making a histogram, and comparing the binding capacity of the antibody with the new coronavirus S protein and bovine serum albumin. The same procedure as described above was carried out by replacing the phage-displayed F5 antibody solution with F10 or H9Histograms were generated comparing the binding capacity of the antibodies to the new coronavirus S protein and bovine serum albumin.
FIG. 6 shows the results of the detection of the virus S protein by the E11 antibody Fab fragment in combination with phage-displayed F5, F10 and H9, respectively. The horizontal axis represents the name of the antibody combined with E11, and the vertical axis represents the absorbance of the solution in the wells of the enzyme. The absorbance of the wells containing the viral S protein ELISA in the solution of E11 combined with F5 was 0.36, while the absorbance of the wells with BSA added was 0.02, indicating that the combination of E11 and F5 can be used to detect the novel coronavirus S protein in solution. Similarly, similar results were obtained with the combination of the E11 antibody fragment with F10 or H9, indicating that the combination of the E11 antibody with F5, F10 or H9 can be used to detect whether the sample contains the new coronavirus S protein or new coronavirus.
Sequence listing
<110> Shandong broad-and-Zheng Bio-medicine Co., Ltd
<120> monoclonal antibody F5 against the novel coronavirus SARS-CoV-2
<130> FA20210701A-4
<141> 2020-07-01
<160> 54
<170> SIPOSequenceListing 1.0
<210> 1
<211> 348
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcaaat attcatgcga gtggtatgcg tacatcgtac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtga gaaaagtagt 300
ggtacgtttg acttctgggg ccagggaacc ctggtcaccg tctcgagc 348
<210> 2
<211> 40
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
tcgcggccca gccggccatg gccgaggtgc agctgttgga 40
<210> 3
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tgagacccac tccagcccct tccct 25
<210> 4
<211> 58
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
tggagtgggt ctcannkatt nnknnknnkg gtnnknnkac annktacgct gactccgt 58
<210> 5
<211> 58
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ttccctggcc ccamnnmnnm nnmnnmnnmn nmnnmnnmnn acagtaatat acggccgt 58
<210> 6
<211> 36
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
tgagctcgag acggtgacca gggttccctg gcccca 36
<210> 7
<211> 324
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctatctt ggatgccatt tgcaaagtgg ggtcccatca 180
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtggacag gctggaggac ggggattgag cttcggccaa 300
gggaccaagg tggaaatcaa acgg 324
<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
ctcagtcgac ggacatccag atgacccagt 30
<210> 9
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
aggagcttag gggctttccc tggttt 26
<210> 10
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
aaagccccta agctcctgat ctatnnknnk nnknnkttgc aaagtggggt 50
<210> 11
<211> 57
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
ttggtccctt ggccgaamnn mnnmnnmnnm nnmnnmnnmn nmnnacagta gtaagtt 57
<210> 12
<211> 44
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
gcctgcggcc gcccgtttga tttccacctt ggtcccttgg ccga 44
<210> 13
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 13
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Thr Asn Ser Gly Ser Ser Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Thr Asp Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 14
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 15
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 15
Ile Thr Asn Ser Gly Ser Ser Thr
1 5
<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 16
Ala Lys Gly Thr Asp Ala Phe Asp Tyr
1 5
<210> 17
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 17
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Cys Ser Pro Ala
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 18
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 18
Gln Ser Ile Ser Ser Tyr
1 5
<210> 19
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 19
Ala Ala Ser
1
<210> 20
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 20
Gln Gln Ser Asn Cys Ser Pro Ala Thr
1 5
<210> 21
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 21
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Asp Ser Ser Gly Tyr Tyr Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asn Ser Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 22
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 22
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 23
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 23
Ile Asp Ser Ser Gly Tyr Tyr Thr
1 5
<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 24
Ala Lys Asn Ser Asp Ser Phe Asp Tyr
1 5
<210> 25
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 25
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asp Gly Pro Asn
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 26
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 26
Gln Ser Ile Ser Ser Tyr
1 5
<210> 27
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 27
Ser Ala Ser
1
<210> 28
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 28
Gln Gln Tyr Asp Asp Gly Pro Asn Thr
1 5
<210> 29
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 29
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Asp Ser Ala Gly Asn Ser Thr Thr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asn Asp Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 30
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 30
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 31
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 31
Ile Asp Ser Ala Gly Asn Ser Thr
1 5
<210> 32
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 32
Ala Lys Asn Asp Ser Ser Phe Asp Tyr
1 5
<210> 33
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 33
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Trp Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Asp Gly Pro Asp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 34
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 34
Gln Ser Ile Ser Ser Tyr
1 5
<210> 35
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 35
Ser Ala Ser
1
<210> 36
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 36
Gln Gln Tyr Ser Asp Gly Pro Asp Thr
1 5
<210> 37
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 37
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asp Ser Ala Gly Tyr Tyr Thr Thr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ser Asp Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 38
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 38
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 39
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 39
Ile Asp Ser Ala Gly Tyr Tyr Thr
1 5
<210> 40
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 40
Ala Lys Asp Ser Asp Thr Phe Asp Tyr
1 5
<210> 41
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 41
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Ser Thr Pro Ala
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 42
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 42
Gln Ser Ile Ser Ser Tyr
1 5
<210> 43
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 43
Ala Ala Ser
1
<210> 44
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 44
Gln Gln Ala Tyr Ser Thr Pro Ala Thr
1 5
<210> 45
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 45
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Asp Ile Thr Asp Asn Gly Ala Ser Thr Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ser Thr Asn Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 46
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 46
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 47
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 47
Ile Thr Asp Asn Gly Ala Ser Thr
1 5
<210> 48
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 48
Ala Lys Ser Thr Asn Thr Phe Asp Tyr
1 5
<210> 49
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 49
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Ile Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asn Ser Asn Ser Pro Ser
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 50
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 50
Gln Ser Ile Ser Ser Tyr
1 5
<210> 51
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 51
Asp Ala Ser
1
<210> 52
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 52
Gln Gln Asn Ser Asn Ser Pro Ser Thr
1 5
<210> 53
<211> 348
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 53
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcannk attnnknnkn nkggtnnknn kacannktac 180
gctgactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtnn knnknnknnk 300
nnknnknnkn nknnktgggg ccagggaacc ctggtcaccg tctcgagc 348
<210> 54
<211> 324
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 54
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctatnnk nnknnknnkt tgcaaagtgg ggtcccatca 180
aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtnnknnk nnknnknnkn nknnknnknn kttcggccaa 300
gggaccaagg tggaaatcaa acgg 324
Claims (4)
1. Monoclonal antibody F5 directed against the novel coronavirus SARS-CoV-2, characterized in that:
the amino acid sequence of the heavy chain variable region of the F5 antibody is SEQ ID NO: 29, CDRH1 amino acid sequence is SEQ ID NO: 30, of a nitrogen-containing gas; the amino acid sequence of CDRH2 is SEQ ID NO: 31; the amino acid sequence of CDRH3 is SEQ ID NO: 32, a first step of removing the first layer;
the amino acid sequence of the variable region of the F5 antibody light chain is SEQ ID NO: 33, CDRL1 amino acid sequence of SEQ ID NO: 34; the amino acid sequence of CDRL2 is SEQ ID NO: 35; the amino acid sequence of CDRL3 is SEQ ID NO: 36.
2. the monoclonal antibody F5 directed against the novel coronavirus SARS-CoV-2 of claim 1, wherein: the application in preparing the new coronaviruses SARS-CoV-2 detecting product.
3. The monoclonal antibody F5 directed against the novel coronavirus SARS-CoV-2 of claim 1, wherein: in the preparation of medicine for inhibiting new coronavirus SARS-CoV-2 and its application in preparing medicine preparation for treating diseases caused by new coronavirus SARS-CoV-2.
4. Any of the engineered monoclonal antibodies characterized in that its antigen binding fragment is an antibody fragment selected from the group consisting of monoclonal antibody F5 against the novel coronavirus SARS-CoV-2 according to claim 1, including Fab, Fab '-SH, Fv, scFv or (Fab') 2 fragments.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110745540.2A CN113278068B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody F5 against novel coronavirus SARS-CoV-2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010499744.8A CN111778218B (en) | 2020-06-04 | 2020-06-04 | Phage display antibody library and monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained based on panning of phage display antibody library |
CN202110745540.2A CN113278068B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody F5 against novel coronavirus SARS-CoV-2 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010499744.8A Division CN111778218B (en) | 2020-06-04 | 2020-06-04 | Phage display antibody library and monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained based on panning of phage display antibody library |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113278068A true CN113278068A (en) | 2021-08-20 |
CN113278068B CN113278068B (en) | 2023-11-10 |
Family
ID=72754645
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110745540.2A Active CN113278068B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody F5 against novel coronavirus SARS-CoV-2 |
CN202110747989.2A Active CN113429478B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody H9 against novel coronavirus SARS-CoV-2 |
CN202110744069.5A Active CN113336846B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody E11 against novel coronavirus SARS-CoV-2 |
CN202110747988.8A Active CN113444170B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody F10 against novel coronavirus SARS-CoV-2 |
CN202010499744.8A Active CN111778218B (en) | 2020-06-04 | 2020-06-04 | Phage display antibody library and monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained based on panning of phage display antibody library |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110747989.2A Active CN113429478B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody H9 against novel coronavirus SARS-CoV-2 |
CN202110744069.5A Active CN113336846B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody E11 against novel coronavirus SARS-CoV-2 |
CN202110747988.8A Active CN113444170B (en) | 2020-06-04 | 2020-06-04 | Monoclonal antibody F10 against novel coronavirus SARS-CoV-2 |
CN202010499744.8A Active CN111778218B (en) | 2020-06-04 | 2020-06-04 | Phage display antibody library and monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained based on panning of phage display antibody library |
Country Status (1)
Country | Link |
---|---|
CN (5) | CN113278068B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115873103A (en) * | 2021-09-22 | 2023-03-31 | 东莞市朋志生物科技有限公司 | Antibody for resisting novel coronavirus N protein, preparation method and application thereof |
CN115894675A (en) * | 2023-02-03 | 2023-04-04 | 康复大学(筹) | New monoclonal antibody of coronavirus SARS-CoV-2 nucleocapsid protein and its application |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20221893A1 (en) | 2020-04-02 | 2022-12-13 | Regeneron Pharma | ANTIBODIES AGAINST SARS-COV-2 SPICLE GLYCOPROTEIN AND ANTIGEN-BINDING FRAGMENTS |
CN111793129B (en) * | 2020-07-28 | 2021-09-24 | 上海市公共卫生临床中心 | Antibody or antigen binding fragment thereof specifically binding to coronavirus |
KR20220054080A (en) * | 2020-10-23 | 2022-05-02 | 주식회사 와이바이오로직스 | ANTIBODY SPECIFICALLY BINDING TO SARS-CoV-2 SPIKE PROTEIN AND USES THEREOF |
CN112239500B (en) * | 2020-10-29 | 2022-01-07 | 东莞市朋志生物科技有限公司 | Antibody against novel coronavirus and kit for detecting novel coronavirus |
CN114426574A (en) * | 2020-10-29 | 2022-05-03 | 中国科学院武汉病毒研究所 | Novel coronavirus neutralizing human monoclonal antibody and application thereof |
WO2022095968A1 (en) * | 2020-11-06 | 2022-05-12 | Shanghaitech University | ANTIBODIES AGAINST SARS-CoV-2 SPIKE PROTEIN |
CN112430265B (en) * | 2020-11-23 | 2022-04-12 | 中国疾病预防控制中心病毒病预防控制所 | Humanized anti-neocoronavirus neutralizing antibody nCoV-61 and application thereof |
CN112574299B (en) * | 2020-11-25 | 2023-03-21 | 苏州方科生物科技有限公司 | Human source antibody of novel coronavirus specific antigen peptide, preparation method and use |
CN112795695B (en) * | 2020-12-31 | 2023-06-02 | 湖南中医药大学 | Fluorescent PCR detection kit and detection method for detecting novel coronavirus |
WO2022188829A1 (en) * | 2021-03-10 | 2022-09-15 | 上海君实生物医药科技股份有限公司 | Sars-cov-2 antibody and application thereof |
CN113045647B (en) * | 2021-03-22 | 2022-04-26 | 南京传奇生物科技有限公司 | Neutralizing antibody of novel coronavirus SARS-CoV-2 and application thereof |
CN113234148A (en) * | 2021-05-19 | 2021-08-10 | 武汉菲沙基因组医学有限公司 | Fully human-derived novel crown IgK single-chain antibody and application thereof |
CN113402603B (en) * | 2021-06-09 | 2022-05-03 | 陕西理工大学 | Avian single-chain antibody for resisting SARS-CoV-2 virus S1 protein and its application |
CN113563483B (en) * | 2021-08-09 | 2024-02-02 | 广州明药科技有限公司 | Phage display novel coronavirus capsid protein and application |
WO2023046057A1 (en) * | 2021-09-24 | 2023-03-30 | 南京金斯瑞生物科技有限公司 | Monoclonal antibody against sars-cov-2 spike protein l452r mutant and use thereof |
WO2023070310A1 (en) * | 2021-10-26 | 2023-05-04 | 中国科学院深圳先进技术研究院 | Anti-sar-cov-2 fully humanized monoclonal antibody and preparation method therefor and application thereof |
CN114106166B (en) * | 2022-01-29 | 2022-05-06 | 中国疾病预防控制中心病毒病预防控制所 | Humanized anti-neocoronavirus neutralizing antibody D2 and application thereof |
CN115850455A (en) * | 2022-02-27 | 2023-03-28 | 武汉滨会生物科技股份有限公司 | Monoclonal antibody aiming at novel coronavirus spike protein and application |
CN115073594A (en) * | 2022-06-08 | 2022-09-20 | 四川大学华西医院 | Single-chain antibody of S2 protein on surface of anti-new coronavirus SARS-CoV-2 mutant strain, preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111088283A (en) * | 2020-03-20 | 2020-05-01 | 苏州奥特铭医药科技有限公司 | mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine |
CN111217920A (en) * | 2020-03-10 | 2020-06-02 | 河北精硕生物科技有限公司 | N-S dominant epitope fusion protein of new coronavirus, preparation method and application thereof, expression protein, microorganism, application thereof and kit |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002253262A (en) * | 2001-03-05 | 2002-09-10 | Frontier Science Co Ltd | Antibody-forming transgenic plant |
CN101260156A (en) * | 2002-06-28 | 2008-09-10 | 多曼蒂斯有限公司 | Immunoglobulin single variant antigen binding domain and specific construct thereof |
WO2006095180A2 (en) * | 2005-03-10 | 2006-09-14 | Ultra Biotech Limited | Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars |
EA201401134A1 (en) * | 2011-02-11 | 2015-05-29 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | HLA-restructured peptidospecific antigen binding proteins |
CN102492037B (en) * | 2011-12-09 | 2013-10-30 | 华中农业大学 | High affinity fusarium specific single-chain antibody and preparation method thereof |
CN102732974B (en) * | 2012-07-16 | 2014-01-15 | 百泰生物药业有限公司 | Method for constructing phage antibody libraries and CD6-resisting antibody obtained by screening by using phage antibody libraries |
CN103806110A (en) * | 2012-11-06 | 2014-05-21 | 北京出入境检验检疫局检验检疫技术中心 | Phage antibody library and application thereof in avian influenza immunodetection |
CN103361741B (en) * | 2013-07-04 | 2014-11-05 | 潍坊科技学院 | Phage antibody library and application thereof in content determination of clenbuterol hydrochloride |
EP3261665A1 (en) * | 2015-02-24 | 2018-01-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
CN105131116B (en) * | 2015-09-25 | 2018-10-09 | 中国人民解放军第四军医大学 | The humanization modified of targeting HER2 is internalized by single-chain antibody P1h3 and preparation method and application |
CN106749656B (en) * | 2016-11-11 | 2018-04-13 | 郑州师范学院 | A kind of anti-mouse RCN3 protein monoclonal ScFv antibody and its Panning methods |
CN106519027B (en) * | 2016-11-11 | 2019-09-17 | 深圳先进技术研究院 | The full human monoclonal antibody 5J13 of anti-H7N9 and its preparation method and application |
CN108191976A (en) * | 2017-12-18 | 2018-06-22 | 青岛珅奥基生物工程有限公司 | A kind of anti-36 monoclonal antibodies of ER- α |
CN109738645B (en) * | 2018-12-26 | 2021-10-12 | 山东宽和正生物医药有限公司 | Non-competitive enzyme-linked immunoassay method for detecting clenbuterol hydrochloride content |
CN111217919B (en) * | 2020-03-04 | 2020-12-01 | 中山大学 | Novel coronavirus S protein double-region subunit nano vaccine based on pyrococcus ferritin |
CN111217918B (en) * | 2020-03-04 | 2020-11-10 | 中山大学 | Novel coronavirus S protein double-region subunit nano vaccine based on 2, 4-dioxotetrahydropteridine synthase |
-
2020
- 2020-06-04 CN CN202110745540.2A patent/CN113278068B/en active Active
- 2020-06-04 CN CN202110747989.2A patent/CN113429478B/en active Active
- 2020-06-04 CN CN202110744069.5A patent/CN113336846B/en active Active
- 2020-06-04 CN CN202110747988.8A patent/CN113444170B/en active Active
- 2020-06-04 CN CN202010499744.8A patent/CN111778218B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111217920A (en) * | 2020-03-10 | 2020-06-02 | 河北精硕生物科技有限公司 | N-S dominant epitope fusion protein of new coronavirus, preparation method and application thereof, expression protein, microorganism, application thereof and kit |
CN111088283A (en) * | 2020-03-20 | 2020-05-01 | 苏州奥特铭医药科技有限公司 | mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115873103A (en) * | 2021-09-22 | 2023-03-31 | 东莞市朋志生物科技有限公司 | Antibody for resisting novel coronavirus N protein, preparation method and application thereof |
CN115894675A (en) * | 2023-02-03 | 2023-04-04 | 康复大学(筹) | New monoclonal antibody of coronavirus SARS-CoV-2 nucleocapsid protein and its application |
CN115894675B (en) * | 2023-02-03 | 2023-11-14 | 康复大学(筹) | New coronavirus SARS-CoV-2 nucleocapsid protein monoclonal antibody and its application |
Also Published As
Publication number | Publication date |
---|---|
CN113336846A (en) | 2021-09-03 |
CN113444170B (en) | 2023-11-10 |
CN111778218A (en) | 2020-10-16 |
CN113278068B (en) | 2023-11-10 |
CN113444170A (en) | 2021-09-28 |
CN111778218B (en) | 2021-08-10 |
CN113429478B (en) | 2023-11-10 |
CN113336846B (en) | 2023-11-10 |
CN113429478A (en) | 2021-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111778218B (en) | Phage display antibody library and monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained based on panning of phage display antibody library | |
CN111995675B (en) | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof | |
CN113264998B (en) | Single-chain antibody of S1 protein on surface of anti-new coronavirus SARS-CoV-2 and application thereof | |
CN111848789B (en) | Single chain antibody for resisting SARS-COV-2 virus S protein and its use | |
CN113150129B (en) | Single-chain antibody for resisting S2 protein on surface of new coronavirus SARS-CoV-2 and application thereof | |
WO2022110742A1 (en) | Humanized antibody against novel coronavirus-specific antigenic peptides, preparation method and use | |
CN108017712B (en) | Protein skeleton derived from shark antibody and application thereof | |
CN116253797B (en) | Anti-novel coronavirus Spike protein antibody and application thereof | |
CN112300274B (en) | Human source antibody of novel coronavirus specific antigen peptide, preparation method and use | |
WO2022061594A1 (en) | Sars-cov-2 spike protein binding molecule and use thereof | |
WO2023125520A1 (en) | CAMEL-DERIVED NANOBODY WITH HIGH-AFFINITY FOR α, β, γ AND δ MUTANT STRAINS OF SARS-COV-2 | |
WO2023216623A1 (en) | CAMEL-DERIVED HIGH-AFFINITY NANOANTIBODY AGAINST SARS-COV-2 α, γ, δ AND ο MUTANTS | |
Zheng et al. | Vaccine Molecule Design Based on Phage Display and Computational Modeling against Rhabdovirus | |
CN114773465B (en) | Single-domain antibody VHH-3 aiming at S protein of new coronavirus omicron strain, coding sequence and application | |
CN110845607B (en) | H1N1 influenza virus antibody and application thereof in H1N1 virus ultramicro-detection | |
Cortay et al. | Selection of single-chain antibodies that specifically interact with vesicular stomatitis virus (VSV) nucleocapsid and inhibit viral RNA synthesis | |
CN117069830A (en) | Nanometer antibody for novel coronavirus and application thereof | |
CN113943367A (en) | Single domain antibodies against novel coronaviruses, kits and medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |